Medicare Enrolled
Dr. Faisal Musa, MD
Hematology & Oncology · Dearborn, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Musa from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Musa?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Musa
Dr. Faisal Musa is a hematology & oncology specialist in Dearborn, MI, with 17 years of NPI registration. Based on federal Medicare data, Dr. Musa performed 156,331 Medicare services across 3,317 unique beneficiaries.
Between the years covered by Open Payments, Dr. Musa received a total of $921,798 from 64 pharmaceutical and/or device companies across 1212 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Musa is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 2% volume in MI
$921,798 industry payments
Medicare Practice Summary
Medicare Utilization ↗156,331
Medicare services
Top 2% in MI for hematology & oncology
3,317
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~9,196 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
41,820 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 27,400 | $43 | $165 |
| Denosumab injection (Prolia/Xgeva) | 26,820 | $18 | $71 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
26,250 | $1 | $4 |
| Injection, atezolizumab, 10 mg | 11,772 | $64 | $246 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,300 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,972 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,434 | $8 | $23 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,387 | $96 | $376 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,250 | $1 | $4 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
675 | $11 | $42 |
| Pegfilgrastim-jmdb injection An injection of pegfilgrastim-jmdb, a biosimilar medication. The dose specified is 0.5 mg. |
588 | $98 | $378 |
| Anti-nausea injection (ondansetron/Zofran) | 568 | $0 | $1 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
549 | $104 | $443 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
451 | $12 | $51 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
361 | $2 | $8 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
343 | $1 | $5 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
300 | $63 | $206 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
288 | $87 | $341 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
265 | $135 | $576 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
255 | $1 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
244 | $138 | $528 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
237 | $7 | $27 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
207 | $8 | $10 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
182 | $50 | $221 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
167 | $57 | $247 |
| New patient office visit, complex (60-74 min) | 156 | $167 | $648 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
155 | $67 | $263 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
121 | $93 | $294 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
112 | $23 | $96 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
101 | $23 | $94 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
100 | $51 | $214 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
84 | $27 | $98 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
71 | $1 | $4 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
59 | $66 | $247 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
51 | $44 | $185 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
42 | $20 | $87 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
39 | $65 | $267 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
36 | $78 | $328 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
33 | $140 | $525 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
31 | $2 | $8 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
25 | $10 | $42 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
16 | $30 | $123 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
14 | $99 | $392 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
44.2% high complexity
53.0% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$921,798
Total received (2018-2024)
Avg $131,685/year across 7 years
Top 0% in MI for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
64
Companies
1,212
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$883,873 (95.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$33,637 (3.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,520 (0.4%)
Other
Charitable contributions, space rental, and other categories
$767 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$227,580
2023
$202,383
2022
$158,218
2021
$157,400
2020
$16,640
2019
$126,328
2018
$33,250
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$96,090
Daiichi Sankyo Inc.
$53,896
AstraZeneca Pharmaceuticals LP
$30,425
Astellas Pharma US Inc
$13,700
Merck Sharp & Dohme LLC
$13,004
EMD Serono, Inc.
$11,063
Deciphera Pharmaceuticals Inc.
$3,388
Incyte Corporation
$2,652
GlaxoSmithKline, LLC.
$2,306
Novartis Pharmaceuticals Corporation
$147
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$129
Axsome Therapeutics, Inc.
$118
ASD Specialty Healthcare, LLC
$72
BeiGene USA, Inc.
$56
RECORDATI_RARE_DISEASES_INC.
$56
Eisai Inc.
$51
JAZZ PHARMACEUTICALS INC.
$40
Celgene Corporation
$37
PFIZER INC.
$37
Genentech USA, Inc.
$28
Acrotech Biopharma Inc.
$24
Takeda Pharmaceuticals U.S.A., Inc.
$22
SOBI, INC
$21
Blueprint Medicines Corporation
$21
Alexion Pharmaceuticals, Inc.
$21
Genmab U.S., Inc.
$21
Aveo Pharmaceuticals, Inc.
$20
SERVIER PHARMACEUTICALS LLC
$19
Agios Pharmaceuticals, Inc.
$19
Janssen Biotech, Inc.
$18
Janssen Pharmaceuticals, Inc
$18
ARRAY BIOPHARMA INC
$17
Ipsen Biopharmaceuticals, Inc
$16
Boston Scientific Corporation
$15
ABBVIE INC.
$14
Top 3 companies account for 79.3% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$335,038
Regeneron Healthcare Solutions, Inc.
$267,281
Merck Sharp & Dohme LLC
$56,470
AstraZeneca Pharmaceuticals LP
$54,027
GENZYME CORPORATION
$47,919
Amgen Inc.
$34,338
AMAG Pharmaceuticals, Inc.
$32,930
Astellas Pharma US Inc
$29,578
Pharmacosmos Therapeutics Inc.
$15,419
EMD Serono, Inc.
$11,063
Sobi, Inc
$8,864
SOBI, INC
$6,356
Shield Therapeutics Inc
$4,878
Deciphera Pharmaceuticals Inc.
$3,388
Incyte Corporation
$2,677
Karyopharm Therapeutics Inc.
$2,445
GlaxoSmithKline, LLC.
$2,306
MorphoSys, US Inc.
$1,467
Seagen Inc.
$1,365
Novartis Pharmaceuticals Corporation
$1,020
Boehringer Ingelheim Pharmaceuticals, Inc.
$260
PFIZER INC.
$232
Genentech USA, Inc.
$217
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Bayer Healthcare Pharmaceuticals Inc.
$151
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$129
Celgene Corporation
$119
Axsome Therapeutics, Inc.
$118
Foundation Medicine, Inc.
$115
Exelixis Inc.
$93
BeiGene USA, Inc.
$86
RECORDATI_RARE_DISEASES_INC.
$82
Sirtex Medical Inc
$79
ARRAY BIOPHARMA INC
$72
Eisai Inc.
$72
ASD Specialty Healthcare, LLC
$72
Gilead Sciences, Inc.
$69
Takeda Pharmaceuticals U.S.A., Inc.
$63
Janssen Biotech, Inc.
$57
Acrotech Biopharma Inc.
$48
PharmaEssentia USA Corporation
$47
Kite Pharma, Inc.
$43
Blueprint Medicines Corporation
$42
JAZZ PHARMACEUTICALS INC.
$40
AVEO Pharmaceuticals, Inc.
$39
G1 Therapeutics, Inc.
$38
Aveo Pharmaceuticals, Inc.
$36
Ipsen Biopharmaceuticals, Inc
$34
Janssen Pharmaceuticals, Inc
$33
ABBVIE INC.
$30
Bayer HealthCare Pharmaceuticals Inc.
$30
Alnylam Pharmaceuticals Inc.
$26
E.R. Squibb & Sons, L.L.C.
$26
Sun Pharmaceutical Industries Inc.
$23
Alexion Pharmaceuticals, Inc.
$21
Genmab U.S., Inc.
$21
SERVIER PHARMACEUTICALS LLC
$19
Agios Pharmaceuticals, Inc.
$19
EISAI INC.
$18
MAYNE PHARMA INC.
$17
Verity Pharmaceuticals Inc.
$17
CTI BioPharma Corp.
$16
Lilly USA, LLC
$15
Boston Scientific Corporation
$15
Top 3 companies account for 71.5% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · ALUNBRIG · AYVAKIT · Alecensa · Auvelity · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · CAPLYTA · COSELA · CREON · Columvi · DARZALEX · DOPTELET · Doptelet · ELITEK · ENHERTU · ENTRESTO · Enhertu · Epkinly · FARXIGA · FERAHEME · FOTIVDA · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · GILOTRIF · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JARDIANCE · JEVTANA · KEYTRUDA · KISQALI · Kadcyla · Kerendia · LIBTAYO · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · Monoferric · Nplate · OJJAARA · ONPATTRO · ONUREG · OPDUALAG · Onivyde · PADCEV · PANHEMATIN · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · QINLOCK · REBLOZYL · RETEVMO · SANCUSO · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SYLVANT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Tecentriq · Trodelvy · ULTOMIRIS · Vanflyta · Venclexta · Vonjo · XARELTO · XPOVIO · XTANDI · Xospata · Xtandi · YONSA · Yescarta · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in MI.
Geographic Context
Hematology & oncology specialists within 10 mi
125
Per 100K population
7.0
County median income
$59,521
Nearest hospital
BEAUMONT HOSPITAL - DEARBORN
3.8 mi
3.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Musa is a mixed practice specialist, with above-average Medicare volume (top 2% in MI), with speaking/promotional industry engagement in the top 0% of MI peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Musa experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Musa performed 41,820 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Musa receive payments from pharmaceutical companies?
Yes. Dr. Musa received a total of $921,798 from 64 companies across 1,212 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Musa's costs compare to other hematology & oncology specialists in Dearborn?
Dr. Musa's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Musa) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Dearborn
Browse hematology & oncology specialists in Dearborn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MI
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MI
Which MI hematology & oncology specialists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology